==== Front
Biochem Soc Trans
Biochem Soc Trans
BST
Biochemical Society Transactions
0300-5127
1470-8752
Portland Press Ltd.

37199495
BST-51-1047
10.1042/BST20221037
Gene Expression & Regulation
Host-Microbe Interactions
Immunology & Inflammation
Microbiology
Virology
Review Articles
Mechanisms of impairment of interferon production by SARS-CoV-2
Hoang Huy-Dung
Naeli Parisa
Alain Tommy
http://orcid.org/0000-0002-5129-7081
Jafarnejad Seyed Mehdi
1 Children's Hospital of Eastern Ontario Research Institute, Department of Biochemistry, Microbiology and Immunology, University of Ottawa, Ottawa, ON K1H 5B2, Canada
2 Patrick G Johnston Centre for Cancer Research, Queen's University Belfast, Belfast, Northern Ireland BT9 7AE, U.K.
Correspondence: Seyed Mehdi Jafarnejad (sm.jafarnejad@qub.ac.uk)
28 6 2023
18 5 2023
51 3 10471056
12 1 2023
2 5 2023
4 5 2023
© 2023 The Author(s)
2023
https://creativecommons.org/licenses/by/4.0/ This is an open access article published by Portland Press Limited on behalf of the Biochemical Society and distributed under the Creative Commons Attribution License 4.0 (CC BY). Open access for this article was enabled by the participation of Queen's University Belfast in an all-inclusive Read & Publish agreement with Portland Press and the Biochemical Society under a transformative agreement with JISC.

Interferons (IFNs) are crucial components of the cellular innate immune response to viral infections. The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has shown a remarkable capacity to suppress the host IFN production to benefit viral replication and spread. Thus far, of the 28 known virus-encoded proteins, 16 have been found to impair the host's innate immune system at various levels ranging from detection and signaling to transcriptional and post-transcriptional regulation of expression of the components of the cellular antiviral response. Additionally, there is evidence that the viral genome encodes non-protein-coding microRNA-like elements that could also target IFN-stimulated genes. In this brief review, we summarise the current state of knowledge regarding the factors and mechanisms by which SARS-CoV-2 impairs the production of IFNs and thereby dampens the host's innate antiviral immune response.

antiviral immunity
coronavirus
innate immunity
interferons
NSP2
SARS-CoV-2
==== Body
pmcSARS-CoV-2 infection and interferons

Coronavirus Disease 2019 (COVID-19) is caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), a member of the Coronaviridae family and closely related to SARS-CoV and Middle East Respiratory Syndrome (MERS) coronaviruses [1]. Certain infected individuals with SARS-CoV-2 can experience severe symptoms that include thromboembolic complications, acute respiratory distress syndrome, tissue damage, and cardiac injury with potentially fatal consequences [2]. These severe COVID-19 cases are characterised by hyperinflammatory response resulting in multisystem organ failure and occurs more frequently with increased patient's age [3–6]. Localised and/or systemic inflammation, characterised by excessive production of certain cytokines such as Interleukin-6 (IL-6), IL-8, and TNFα has been linked to promoting such severe symptoms [7]. However, several lines of evidence indicate a highly protective role for another class of cytokines called interferons (IFNs), at least in the initial stages of SARS-CoV-2 infection. These include a host antiviral response to SARS-CoV-2 in nasal epithelial cells that is dominated by IFN signaling [8], repression of in vitro SARS-CoV-2 replication by type I IFN [9,10], and poor viral replication and less severe COVID-19 symptoms in individuals with a robust IFN-induced antiviral response in the early phase of infection [11,12]. Conversely, impaired or delayed production of type I IFN is associated with higher viral titers in blood and pernicious symptoms in late-stage patients [13,14]. Higher severity of SARS-CoV-2 infection is observed in individuals with various types of genetic deficiencies related to immunological defects affecting type I and III IFNs production [15–18] and Interferon-Stimulated Genes (ISGs) [19], or the presence of neutralising auto-antibodies against IFNs [18,20,21].

IFNs are important cytokines that exist in all jawed vertebrates. Their primordial roles are to confer protection against invading pathogens [22]. Human genome encodes three major classes of IFN: Type I, II, and III (Table 1). While type II IFNs are primarily produced by activated immune cells (e.g. NK and T-cells), types I and III can be produced by almost all cell types and are crucial as the first line of innate immune response to viral infections. In this review, we will highlight the important roles of type I and III IFNs in cellular responses to SARS-CoV-2 infection with a focus on the mechanisms by which SARS-CoV-2 impairs IFN production.

Table 1 Different types of Interferons and their upstream and downstream pathways

Type	Subtypes	Tissue specificity	Receptors	Downstream signaling pathway	Biological outcomes	
I	α1, α2, α4, α5, α6, α7, α8, α10, α13, α14, α16, α17, α21, β, ε, κ, ω	-	IFNAR1/IFN AR2	JAK/STAT/IRF-9	Cellular and humoral immune responses	
II	γ	NK, CD4+ & CD8+ T-cells	IFNGR1/IFN GR2	JAK/STAT JAK/STAT/IRF-9	Intracellular antiviral programs, polarisation and priming of macrophages to M1 phenotype	
III	λ1, λ2, λ3, λ4	Epithelial cells	IFNLR1/IL10 Rβ	JAK/STAT	Localised immune response in epithelial tissues	

Type I and type III IFNs: the first line of defense against viral infection

Expression of type I and type III IFNs is regulated by a complex mechanism that is initiated by triggering of the pathogen-associated molecular pattern recognition receptors (PRRs). PRRs sense viral pathogen-associated molecular patterns (PAMPs) or host molecules associated with disturbance of homeostasis called danger-associated molecular patterns (DAMPs) [23]. There are five primary PRR families; Toll-like receptors (TLRs), retinoic acid-inducible gene I (RIG-I)-like receptors (RLRs), nucleotide-binding oligomerization domain (NOD)-like receptors (NLRs), C-type lectin receptors (CLRs), and absent from melanoma 2 (AIM2)-like receptors [23]. TLRs and RLRs provide the main mechanisms of detection of SARS-CoV-2 infection.

TLRs are transmembrane proteins localised to the cell surface and in membrane bound organelles such as lysosomes, endosomes, or endolysosomes and they recognise distinct or overlapping PAMPs such as lipids, proteins, and nucleic acids [23]. Upon PAMPs and DAMPs recognition, TLRs generally transduce signals via two key adaptor molecules, MyD88 and TRIF, which initiate signal transduction pathways that result in the activation of IFN regulatory factors (IRFs), NF-κB, or MAP kinases and activation of transcription of genes that encode pro-inflammatory cytokines and type I IFNs (Figure 1). The first contact between SARS-CoV-2 and TLR sensors occurs at the cell surface, where SARS-CoV-2 envelope protein E and spike protein are recognised by TLR2 and TLR4, respectively [24,25]. Upon entering the cells, various SARS-CoV-2 derived molecules, including nucleocapsid (N), envelope (E), and spike (S) proteins, double-strand RNAs (dsRNAs), and single-strand RNAs (ssRNAs) can trigger various TLRs and activate the downstream signaling pathways [26–28]. Intracellular SARS-CoV-2-derived RNAs can also be sensed in the cytoplasm by RLRs (e.g. MDA5, LGP2, and RIG-I) that form a complex with the adaptor protein mitochondrial antiviral signaling (MAVS) [29,30]. This complex subsequently activates TNF receptor-associated factor 3 (TRAF3), TANK-binding kinase 1 (TBK1), and IκB kinase (IKK), which in turn phosphorylate and activate IRF3 and IRF7. Phosphorylated IRF3 and IRF7 form homo- or heterodimers that stimulate transcription of pro-inflammatory cytokines, type I IFNs and ISGs (Figure 1).

Figure 1. Schematic presentation of the mechanisms adopted by SARS-CoV-2 for disruption of the Interferon signaling pathway.

Double-Membrane Vesicles (DMVs) derived from the endoplasmic reticulum membranes protect the dsRNA replication intermediates from recognition by TLRs and RLRs. NSP5 reduces the interaction between RIG-I and TRIM25 and cleaves a small 10-residue fragment at the N-terminal of RIG-I and thereby impairs the ability of RIG-I to activate IRF3. The N protein interacts with TRIM25 and RIG-I and suppresses RIG-I ubiquitination and activation. The M protein binds to and destabilises the RIG-I-MAVS–TBK1 interaction. NSP13 inhibits TBK1, while NSP6 reduces phosphorylation of IRF3. ORF9b inhibits the ubiquitination and activation of NEMO. NSP3 prevents MDA5 activation by removing the ISG15 groups, while blocking IRF3 activation by maintaining its ISGylation status. ORF6 and NSP12 block IRF3 nuclear translocation. NSP16 disrupts the host's mRNA splicing machinery by binding to the U1 and U2 snRNAs. NSP1 interacts with the host NXF1–NXT1 protein complex and prevents the export of cellular mRNAs. ORF6 impairs nuclear export by binding to KPNA2 and the nuclear pore complex proteins Nup98 and Rae1. NSP1 blocks mRNA translation via binding to the 40S ribosomal subunit at the mRNA entry tunnel. NSP14 in cooperation with NSP10 blocks mRNA translation by an unknown mechanism. NSP2 recruits and stabilises the GIGYF2/4EHP cap-dependent translational repressor complex to enhance the microRNA-mediated translational repression of target mRNAs including Ifn1b mRNA that encodes IFN-β. ORF3a promotes the ubiquitination and degradation of JAK2. NSP13 interacts with STAT1 and prevents its JAK1-mediated phosphorylation. The N protein impedes STAT1/2 phosphorylation and nuclear translocation.

The resulting IFNs are subsequently secreted and stimulate downstream signaling through dedicated transmembrane receptors (Table 1) in autocrine and paracrine manners. While receptors for type I IFNs are widely expressed, the receptor for type III is restricted to specific cell types, namely macrophages, neutrophils, respiratory epithelial cells, conventional dendritic cells (DCs) and plasmacytoid dendritic cells (pDCs) [31]. Binding of type I and III IFNs to their respective receptors activates the JAK/STAT signaling pathway, which promotes the formation of the STAT1/2/IRF9 complex and stimulates the transcription of a large number of ISGs that mediate the establishment of an antiviral state (reviewed in [32]). A subset of ISGs can also be transcriptionally induced by other IRFs such as IRF3 [33]. Notably, due to the overlapping downstream signaling cascade for type I and III IFNs, many of their functional outcomes are similar. However, because of differences in the types of cells that express the dedicated receptors and the magnitude and kinetics of the response, distinct biological outcomes can result from activation of type I or type III IFNs. As such, type III IFNs are mainly found to serve as localised front-line defense in respiratory tissues, whereas type I IFNs are mostly produced by pDCs and can trigger both cellular and humoral immune responses to viruses via several pathways, which include inducing the expression of MHC II and co-stimulatory molecules, activating antigen presenting cells (APCs) and natural killer (NK) cells, and promoting the proliferation and differentiation of both CD8+ and CD4+ T-cells [34].

While a robust IFN-mediated antiviral response is required for combating viral infections, an exaggerated response upon viral recognition can lead to adverse consequences such as severe tissue damage [35]. Notably, aberrant expression of type I and III IFNs or dysregulated activation of ISGs has been frequently observed in the tissues or serum samples of patients with autoinflammatory and autoimmune disorders such as systemic lupus erythematosus, rheumatoid arthritis, Sjögren syndrome, and systemic sclerosis [36,37]. This highlights the imperative need for tight control of the expression of IFNs to maintain tissue homeostasis. However, such important and vital mechanisms are often ingeniously co-opted by viruses to dampen the antiviral immune response. SARS-CoV-2 has evolved several ways to target and control the IFN response.

Mechanisms of evasion of IFN production by SARS-CoV-2

The SARS-CoV-2 virion contains four structural proteins: spike (S), envelope (E), membrane (M) and nucleocapsid (N), enveloping a 30 kb single-stranded positive-sense genomic mRNA. Once in the host cell, the genomic mRNA encodes two polyproteins from the open reading frames 1a (ORF1a) and ORF1b, which are subsequently cleaved by two viral proteases into sixteen non-structural proteins (NSP1-16). The viral genome also encodes the four structural (S, E, M and N) and up to ten accessory (3a, 3b, 3c, 6, 7a, 7b, 8, 9b, 9c, and 10) proteins.

The SARS-CoV-2 RNAs are recognised by TLRs, RIG-I, and MDA5 [29,38,39], which should result in the dramatic stimulation of innate immune response and in the transcriptional activation of IFN coding genes. However, overwhelming evidence suggests that SARS-CoV-2 infection induces IFNs and ISGs production only weakly [13,40,41]. Here, we summarise the various mechanisms adopted by SARS-CoV-2 to impair IFN production.

Repression of activation of IFN coding genes

Masking the viral products that trigger the PRRs or blocking downstream signaling pathways are effective mechanisms to limit IFN production and evade the antiviral host response.

Blocking recognition by the host

SARS-CoV-2 employs several strategies to hide its genome and specifically target distinct antiviral proteins to limit the IFN response. SARS-CoV-2 protects its dsRNA replication intermediates from recognition by RLRs by replicating its ssRNA genome in double-membrane vesicles that are derived from the endoplasmic reticulum membranes [42]. The virus can also directly influence the post-translational modifications, protein–protein interactions, and activities of RLRs. The viral protein NSP5 is a highly conserved protease in Coronaviruses which is known to cleave a small 10-residue fragment at the N-terminal of RIG-I thereby impairing the ability of RIG-I to activate IRF3 [43]. NSP5 also reduces the interaction between RIG-I and TRIM25, which is required for the activation of RIG-I via its K63-linked ubiquitination by TRIM25 after recognising viral RNAs [44]. The N protein of SARS-CoV-2, despite being a structural protein, also interacts with TRIM25 and RIG-I, and suppresses RIG-I ubiquitination and activation [45–47].

Disrupting antiviral signaling pathways

Several viral proteins have been shown to block MAVS-induced signaling downstream of RLRs through distinct mechanisms. NSP13 interacts with and inhibits TBK1 phosphorylation at its S172 residue [48] either by blocking TBK1 autophosphorylation or the ability of IKKε to phosphorylate TBK1 [49]. NSP6 also binds to TBK1, leading to reduced downstream phosphorylation of IRF3, although without affecting TBK1 S172 phosphorylation [49]. Additionally, binding of the M protein inhibits the formation of the RIG-I/MAVS/TRAF3/TBK1 complex [50].

The interferon-stimulated gene 15 (ISG15) can conjugate to MDA5 at its caspase activation and recruitment domain through a process known as ISGylation [51]. MDA5 ISGylation induces its oligomerization and triggers activation of innate immunity. Through its papain-like protease (PLpro) activity, NSP3 antagonises MDA5 activation by removing the ISG15 groups [51]. ISGylation of several residues (Lys193, −360, and −366) on IRF3 by HERC5 results in sustained IRF3 activation by attenuating the interaction between Pin1 and IRF3 [52]. The SARS-CoV-2 protein NSP3 was shown to block IRF3 activation by de-ISGylating this important antiviral transcription factor [53]. The virus further inhibits IRF3 activity through ORF6, which blocks IRF3 nuclear translocation by binding to Karyopherin α2 (KPNA2), an importing factor for nuclear translocation of cargos [49]. The viral protein NSP12 also impairs IRF3 nuclear localisation, but not phosphorylation of this transcription factor [54]. Downstream of MAVS, the NFκB signaling pathway is targeted by ORF9b via its inhibition of ubiquitination of the modulator protein NEMO [55].

Interestingly, the JAK/STAT signaling that mediates the antiviral state of cells in an autocrine and paracrine manners downstream of type I IFN is also a target of SARS-CoV-2 disruption, perhaps affecting spread of the virus. The NSP13 protein interacts with STAT1 to prevent JAK1-mediated phosphorylation [56,57], while the N protein impedes STAT1/2 phosphorylation and nuclear translocation [58]. On the other hand, ORF3a promotes the ubiquitination and degradation of JAK2 via up-regulation of the suppressor of cytokine signaling 1 (SOCS1), a component of an E3 ubiquitin ligase complex that suppresses IFN signaling [59]. Through these mechanisms of blocking the recognition of the virus and the activation of the RIG-1/MAVS/TBK1 and the JAK/STAT pathways, SARS-CoV-2 acts to abolish the transcriptional activation of genes that encode type I and type III IFNs and ISGs.

Post-transcriptional regulation of IFN production

Following transcription in the nucleus, mRNAs undergo multiple layers of post-transcriptional processes including splicing, nuclear export, translation, and finally degradation in the cytoplasm. Several lines of evidence have demonstrated that SARS-CoV-2 also employs various mechanisms to modulate virtually every step of post-transcriptional regulation of IFN production.

Interrupting mRNA splicing

Targeting the host splicing machinery is a strategy employed by some viruses to disarm the antiviral response [60,61]. In a screen for interaction between SARS-CoV-2 proteins and human RNAs, NSP16 was found to bind to the U1 and U2 snRNAs, important components of the spliceosome complex [62]. Overexpression of NSP16 disrupts global splicing, resulting in the defective splicing and intron retention in multiple IFN-responsive genes such as ISG15 and RIG-I, thereby impairing IFN signaling upon SARS-CoV-2 infection [62].

Blocking the mRNA nuclear export

Nuclear export of mRNAs is a crucial step in the mammalian gene expression process that is frequently targeted by different viruses to both thwart translation of host mRNAs and suppress the expression of IFN and other antiviral factors [63]. As SARS-CoV-2 completes its replication cycle within the cytoplasm, sabotaging the host nuclear export is a simple strategy to disrupt the cell's innate response without negatively impacting the expression of viral proteins. Genome-wide analysis of mRNA expression and stability upon SARS-CoV-2 infection revealed an accelerated rate of degradation of cellular mRNAs due to inhibition of nuclear mRNA export [64]. Single-molecule visualisation of host mRNAs during SARS-CoV-2 infection showed that in most infected cells SARS-CoV-2 inhibits the release of IFN-encoding mRNAs from their sites of transcription and triggers their decay in the nucleus [65]. NSP1 plays a key role in this process through interaction with the host NXF1–NXT1 protein complex, which is responsible for nuclear export of cellular mRNAs. NSP1 blocks binding of NXF1 to the export adaptors and docks at the nuclear pore complex to prevent the export of cellular mRNAs, including IFN-encoding mRNAs [66]. The viral protein encoded by ORF6 also impairs nuclear export and entraps host mRNAs including those of IFNs through binding to the nuclear pore complex (NPC) proteins Nup98 and Rae1 via its C-terminus [67–69].

Repressing mRNA translation

After being exported to the cytoplasm, cellular mRNAs are translated via the ribosomes with the aid of a large number of translation factors. As transcripts of antiviral genes ultimately need to be translated into protein, shutting down the host's mRNA translation is a strategy exploited by most viruses to allow redirecting the host's ribosomes toward the viral mRNAs and to impede the host antiviral response [70]. Thus, and perhaps not surprisingly, SARS-CoV-2 infection also leads to a reduction in global protein synthesis [62,64]. This effect is primarily attributed to NSP1, which inhibits translation by binding to the 40S small ribosomal subunit at the mRNA entry tunnel, rendering the ribosome inactive and leading to the degradation of the mRNA [64,71,72]. Concomitantly, the viral mRNA translation is maintained through a combination of two main mechanisms: 1. enhanced availability of ribosomes and translation factors due to degradation of cellular mRNAs [64], 2. elevated specific recruitment of ribosomes through a cap-proximal RNA element within the 5′ Un-Translated Region (5′ UTR) of the viral mRNAs that is devoid of guanosines and thus resists NSP1-mediated translation inhibition [73]. Besides NSP1, NSP14 also induces a near-complete shutdown in translation of cellular mRNAs, including those encoding IFN [49,74]. Although the exact mechanism by which NSP14 blocks mRNA translation and how it avoids repressing the translation of the viral mRNA is not clear, its exoribonuclease (ExoN) and N7-methyltransferase (N7-MTase) activities as well as its interaction with NSP10 are required for repression of mRNA translation [74].

In addition to shutting down general cap-dependent translation of cellular mRNAs, SARS-CoV-2 also employs a ‘targeted' mechanism of impairment of the host cell's IFN responses by recruiting the cap-binding and translational repressor eIF4E-homolog protein (4EHP). NSP2 recruits 4EHP through binding to the Grb10-interacting GYF (glycine, tyrosine, phenylalanine) protein 2 (GIGYF2). This interaction stabilises the GIGYF2/4EHP complex that specifically represses translation of Ifnb1 mRNA, thereby impeding IFN-β production [75].

Targeting IFN-related transcripts by microRNAs and microRNA-like non-coding RNAs

4EHP and GIGYF2 mediate the translational repression of mRNAs targeted by microRNAs [69-71]. NSP2 enhances the microRNA-induced translational silencing through interaction with GIGYF2 and stabilisation of the GIGYF2/4EHP complex [76,77]. Once thought to be exclusively a host-related mechanism, microRNAs are also expressed by viruses to control both host and viral gene expression [78]. Studies using small RNA sequencing of SARS-CoV-2 infected cells identified virus-derived short RNA fragments that were later confirmed to be SARS-CoV-2 expressed microRNAs [79,80]. Such virus-derived microRNAs can be loaded into an Argonaute (Ago) protein, the key component of the microRNA-Induced Silencing Complex (miRISC) [80], indicating their ability to engage this machinery and repress the expression of the target RNAs. Notably, production of these virus-derived microRNAs is dependent on the cytoplasmic Dicer enzyme [80], yet independent of nuclear Drosha [78], suggesting that SARS-CoV-2 microRNAs might be expressed and matured in the cytoplasm, consistent with the subcellular location of virus replication. Computational predictions as well as empirical evidence demonstrate that these SARS-CoV-2 encoded microRNAs, most notably the miRNA CoV-miR-O7, could target several mRNAs that encode proteins with important roles in immune-regulatory processes both upstream and downstream of IFNs, such as IRF7, IRF9, STAT2, and ISGs (e.g. ISG15, MX1, and BATF2) [79,80,81,82]. Notably, multiple cellular microRNAs are also known to target the IFN mRNAs [83–85]. The potential role of NSP2 in exacerbating the repression of the target mRNAs of these host and virus-derived microRNAs in repression of the IFN production will be important to delineate.

Perspectives

The extent of the COVID-19 pandemic and its human and economic costs highlights the urgent need to fundamentally understand SARS-CoV-2 virus-host interactions. It is now clear that SARS-CoV-2 has acquired strong capacities to suppress the host IFN response, with an arsenal of proteins and RNA elements targeting virtually every step in the IFN production and signaling cascade.

As new variants continue to emerge, defining the critical IFN-impairing functions of the distinct SARS-CoV-2 proteins, and monitoring how their important residues mutate over time to provide a viral advantage or induce more severe disease is important.

Knowledge of the unique characteristics of the viral proteins that regulate expression of IFNs and innate immune responses could inform novel approaches in protein therapeutics against autoinflammatory and autoimmune diseases.

Acknowledgements

We apologise to colleagues whose work was not cited due to space constraints. We thank Prof R.J.H. Davies for critical reading of the manuscript. Research in the laboratory of S.M.J. is funded in part by the Biotechnology and Biological Sciences Research Council (grant# BB/W008165/1). T.A. acknowledges funding from NSERC, CCSRI and CIHR. Figure 1 was generated with BioRender.com online tool.

Competing Interests

The authors declare that there are no competing interests associated with the manuscript.

Open Access

Open access for this article was enabled by the participation of Queen's University Belfast in an all-inclusive Read & Publish agreement with Portland Press and the Biochemical Society under a transformative agreement with JISC.

Author Contributions

H.D.H. and S.M.J. wrote the manuscript with inputs from PN and TA.

Abbreviations

4EHP eIF4E-homolog protein

ALRs absent from melanoma 2 (AIM2)-like receptors

APCs antigen presenting cells

CLRs C-type lectin receptors

DAMPs danger-associated molecular patterns

dsRNAs double-strand RNAs

ExoN exoribonuclease

GIGYF2 Grb10-interacting GYF (glycine, tyrosine, phenylalanine) protein 2

IFN Interferon

IKK IκB kinase

IL Interleukin-6

IRFs interferon regulatory factors

ISG interferon-stimulated gene

ISGs interferon-stimulated genes

JAK/STAT Janus kinase (JAK)-signal transducer and activator of transcription (STAT)

MAVS mitochondrial antiviral signaling

MHC major histocompatibility complex

N7-MTase N7-methyltransferase

NK natural killer cells

NLRs nucleotide-binding oligomerization domain (NOD)-like receptors

NSP non-structural proteins

ORF open reading frame

PAMPs pathogen-associated molecular patterns

PRRs pattern recognition receptors

RLRs retinoic acid-inducible gene I (RIG-I)-like receptors

SARS-CoV-2 severe acute respiratory syndrome coronavirus 2

ssRNAs single-strand RNAs

TBK1 TANK-binding kinase 1

TLRs Toll-like receptors

TRAF3 TNF receptor-associated factor 3
==== Refs
References

1 Zhou, P., Lou Yang, X., Wang, X.G., Hu, B., Zhang, L., Zhang, W. et al. (2020) A pneumonia outbreak associated with a new coronavirus of probable bat origin. Nature 579 , 270–273 10.1038/s41586-020-2012-7 32015507
2 Huang, C., Wang, Y., Li, X., Ren, L., Zhao, J., Hu, Y. et al. (2020) Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet (London, England) 395 , 497–506 10.1016/S0140-6736(20)30183-5 31986264
3 Guan, W., Ni, Z., Hu, Y., Liang, W., Ou, C., He, J. et al. (2020) Clinical characteristics of Coronavirus disease 2019 in China. N. Engl. J. Med. 382 , 1708–1720 10.1056/NEJMoa2002032 32109013
4 Zhou, F., Yu, T., Du, R., Fan, G., Liu, Y., Liu, Z. et al. (2020) Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet 395 , 1054–1062 10.1016/S0140-6736(20)30566-3 32171076
5 Cao, X. (2020) COVID-19: immunopathology and its implications for therapy. Nat. Rev. Immunol. 20 , 269–270 10.1038/s41577-020-0308-3 32273594
6 Feldstein, L.R., Rose, E.B., Horwitz, S.M., Collins, J.P., Newhams, M.M., Son, M.B.F. et al. (2020) Multisystem inflammatory syndrome in U.S. children and adolescents. N. Engl. J. Med. 383 , 334–346 10.1056/NEJMoa2021680 32598831
7 Del Valle, D.M., Kim-Schulze, S., Huang, H.H., Beckmann, N.D., Nirenberg, S., Wang, B. et al. (2020) An inflammatory cytokine signature predicts COVID-19 severity and survival. Nat. Med. 26 , 1636–1643 10.1038/s41591-020-1051-9 32839624
8 Hatton, C.F., Botting, R.A., Dueñas, M.E., Haq, I.J., Verdon, B., Thompson, B.J. et al. (2021) Delayed induction of type I and III interferons mediates nasal epithelial cell permissiveness to SARS-CoV-2. Nat. Commun. 12 , 7092 10.1038/s41467-021-27318-0 34876592
9 Felgenhauer, U., Schoen, A., Gad, H.H., Hartmann, R., Schaubmar, A.R., Failing, K. et al. (2020) Inhibition of SARS-CoV-2 by type I and type III interferons. J. Biol. Chem. 295 , 13958–13964 10.1074/jbc.AC120.013788 32587093
10 Mantlo, E., Bukreyeva, N., Maruyama, J., Paessler, S. and Huang, C. (2020) Antiviral activities of type I interferons to SARS-CoV-2 infection. Antiviral Res. 179 , 104811 10.1016/j.antiviral.2020.104811 32360182
11 Masood, K.I., Yameen, M., Ashraf, J., Shahid, S., Mahmood, S.F., Nasir, A. et al. (2021) Upregulated type I interferon responses in asymptomatic COVID-19 infection are associated with improved clinical outcome. Sci. Rep. 11 , 22958 10.1038/s41598-021-02489-4 34824360
12 Vinh, D.C., Abel, L., Bastard, P., Cheng, M.P., Condino-Neto, A., Gregersen, P.K. et al. (2021) Harnessing type I IFN immunity against SARS-CoV-2 with early administration of IFN-β. J. Clin. Immunol. 41 , 1425–1442 10.1007/s10875-021-01068-6 34101091
13 Hadjadj, J., Yatim, N., Barnabei, L., Corneau, A., Boussier, J., Smith, N. et al. (2020) Impaired type I interferon activity and inflammatory responses in severe COVID-19 patients. Science 369 , 718–724 10.1126/science.abc6027 32661059
14 Galani, I.E. Rovina, N., Lampropoulou, V., Triantafyllia, V., Manioudaki, M., Pavlos, E. et al. (2021) Untuned antiviral immunity in COVID-19 revealed by temporal type I/III interferon patterns and flu comparison. Nat. Immunol. 22 , 32–40 10.1038/s41590-020-00840-x 33277638
15 Van Der Made, C.I., Simons, A., Schuurs-Hoeijmakers, J., Van Den Heuvel, G., Mantere, T., Kersten, S. et al. (2020) Presence of genetic variants among young men with severe COVID-19. JAMA. 324 , 663–673 10.1001/jama.2020.13719 32706371
16 Fallerini, C., Daga, S., Mantovani, S., Benetti, E., Picchiotti, N., Francisci, D. et al. (2021) Association of Toll-like receptor 7 variants with life-threatening COVID-19 disease in males: findings from a nested case-control study. eLife 10 , e67569 10.7554/eLife.67569 33650967
17 Zhang, Q., Liu, Z., Moncada-Velez, M., Chen, J., Ogishi, M., Bigio, B. et al. (2020) Inborn errors of type I IFN immunity in patients with life-threatening COVID-19. Science 370 , eabd4570 10.1126/science.abd4570 32972995
18 Zhang, Q., Bastard, P., Karbuz, A., Gervais, A., Tayoun, A.A., Aiuti, A. et al. (2022) Human genetic and immunological determinants of critical COVID-19 pneumonia. Nature 603 , 587–598 10.1038/s41586-022-04447-0 35090163
19 Huffman, J.E., Butler-Laporte, G., Khan, A., Pairo-Castineira, E., Drivas, T.G., Peloso, G.M. et al. (2022) Multi-ancestry fine mapping implicates OAS1 splicing in risk of severe COVID-19. Nat. Genet. 54 , 125–127 10.1038/s41588-021-00996-8 35027740
20 Abers, M.S., Rosen, L.B., Delmonte, O.M., Shaw, E., Bastard, P., Imberti, L. et al. (2021) Neutralizing type-I interferon autoantibodies are associated with delayed viral clearance and intensive care unit admission in patients with COVID-19. Immunol. Cell Biol. 99 , 917–921 10.1111/imcb.12495 34309902
21 Wang, E.Y., Mao, T., Klein, J., Dai, Y., Huck, J.D., Jaycox, J.R. et al. (2021) Diverse functional autoantibodies in patients with COVID-19. Nature 595 , 283–288 10.1038/s41586-021-03631-y 34010947
22 Secombes, C.J. and Zou, J. (2017) Evolution of interferons and interferon receptors. Front. Immunol. 8 , 209 10.3389/fimmu.2017.00209 28303139
23 Li, D. and Wu, M. (2021) Pattern recognition receptors in health and diseases. Signal Transduct. Target. Ther. 6 , 291 10.1038/s41392-021-00687-0 34344870
24 Zheng, M., Karki, R., Williams, E.P., Yang, D., Fitzpatrick, E., Vogel, P. et al. (2021) TLR2 senses the SARS-CoV-2 envelope protein to produce inflammatory cytokines. Nat. Immunol. 22 , 829–838 10.1038/s41590-021-00937-x 33963333
25 Khan, S., Shafiei, M.S., Longoria, C., Schoggins, J.W., Savani, R.C. and Zaki, H. (2021) SARS-CoV-2 spike protein induces inflammation via TLR2-dependent activation of the NF-κB pathway. eLife 10 , e68563 10.7554/eLife.68563 34866574
26 Qian, Y., Lei, T., Patel, P.S., Lee, C.H., Monaghan-Nichols, P., Xin, H.-B. et al. (2021) Direct activation of endothelial cells by SARS-CoV-2 nucleocapsid protein is blocked by Simvastatin. J. Virol. 95 , 1396–1417 10.1128/JVI.01396-21
27 Zhao, Y., Kuang, M., Li, J., Zhu, L., Jia, Z., Guo, X. et al. (2021) SARS-CoV-2 spike protein interacts with and activates TLR41. Cell Res. 31 , 818–820 10.1038/s41422-021-00495-9 33742149
28 Salvi, V., Nguyen, H.O., Sozio, F., Schioppa, T., Gaudenzi, C., Laffranchi, M. et al. (2021) SARS-CoV-2-associated ssRNAs activate inflammation and immunity via TLR7/8. JCI insight 6 , e150542 10.1172/jci.insight.150542 34375313
29 Thorne, L.G., Reuschl, A., Zuliani-Alvarez, L., Whelan, M.V.X., Turner, J., Noursadeghi, M. et al. (2021) SARS-CoV-2 sensing by RIG-I and MDA5 links epithelial infection to macrophage inflammation. EMBO J. 40 , e107826 10.15252/embj.2021107826 34101213
30 Yin, X., Riva, L., Pu, Y., Martin-Sancho, L., Kanamune, J., Yamamoto, Y. et al. (2021) MDA5 governs the innate immune response to SARS-CoV-2 in lung epithelial cells. Cell Rep. 34 , 108628 10.1016/j.celrep.2020.108628 33440148
31 Zhou, Z., Hamming, O.J., Ank, N., Paludan, S.R., Nielsen, A.L. and Hartmann, R. (2007) Type III interferon (IFN) induces a type I IFN-like response in a restricted subset of cells through signaling pathways involving both the Jak-STAT pathway and the mitogen-activated protein kinases. J. Virol. 81 , 7749–7758 10.1128/JVI.02438-06 17507495
32 Schoggins, J.W. (2019) Interferon-stimulated genes: what do they all do? Annu. Rev. Virol. 6 , 567–584 10.1146/annurev-virology-092818-015756 31283436
33 Wang, W., Xu, L., Su, J., Peppelenbosch, M.P. and Pan, Q. (2017) Transcriptional regulation of antiviral interferon-stimulated genes. Trends Microbiol. 25 , 573–584 10.1016/j.tim.2017.01.001 28139375
34 Lazear, H.M., Schoggins, J.W. and Diamond, M.S. (2019) Shared and distinct functions of type I and type III interferons. Immunity 50 , 907–923 10.1016/j.immuni.2019.03.025 30995506
35 Crow, M.K., Olferiev, M. and Kirou, K.A. (2019) Type I interferons in autoimmune disease. Annu. Rev. Pathol. 14 , 369–393 10.1146/annurev-pathol-020117-043952 30332560
36 Goel, R.R., Wang, X., O'Neil, L.J., Nakabo, S., Hasneen, K., Gupta, S. et al. (2020) Interferon lambda promotes immune dysregulation and tissue inflammation in TLR7-induced lupus. Proc. Natl Acad. Sci. U.S.A. 117 , 5409–5419 10.1073/pnas.1916897117 32094169
37 Major, J., Crotta, S., Llorian, M., McCabe, T.M., Gad, H.H., Priestnall, S.L. et al. (2020) Type I and III interferons disrupt lung epithelial repair during recovery from viral infection. Science 369 , 712–717 10.1126/science.abc2061 32527928
38 Yamada, T., Sato, S., Sotoyama, Y., Orba, Y., Sawa, H., Yamauchi, H. et al. (2021) RIG-I triggers a signaling-abortive anti-SARS-CoV-2 defense in human lung cells. Nat. Immunol. 22 , 820–828 10.1038/s41590-021-00942-0 33976430
39 Bortolotti, D., Gentili, V., Rizzo, S., Schiuma, G., Beltrami, S., Strazzabosco, G. et al. (2021) Tlr3 and tlr7 rna sensor activation during sars-cov-2 infection. Microorganisms 9 , 1820 10.3390/microorganisms9091820 34576716
40 Blanco-Melo, D., Nilsson-Payant, B.E., Liu, W.C., Uhl, S., Hoagland, D., Møller, R. et al. (2020) Imbalanced host response to SARS-CoV-2 drives development of COVID-19. Cell 181 , 1036–1045 10.1016/j.cell.2020.04.026 32416070
41 Vanderheiden, A., Ralfs, P., Chirkova, T., Upadhyay, A.A., Zimmerman, M.G., Bedoya, S. et al. (2020) Type I and type III interferons restrict SARS-CoV-2 infection of human airway epithelial cultures. J. Virol. 94 , e00985-20 10.1128/JVI.00985-20 32699094
42 Snijder, E.J., Limpens, R.W.A.L., de Wilde, A.H., de Jong, A.W.M., Zevenhoven-Dobbe, J.C., Maier, H.J. et al. (2020) A unifying structural and functional model of the coronavirus replication organelle: tracking down RNA synthesis. PLoS Biol. 18 , e3000715 10.1371/journal.pbio.3000715 32511245
43 Liu, Y., Qin, C., Rao, Y., Ngo, C., Feng, J.J., Zhao, J. et al. (2021) SARS-CoV-2 Nsp5 demonstrates two distinct mechanisms targeting RIG-I and MAVS to evade the innate immune response. MBio. 12 , e0233521 10.1128/mBio.02335-21 34544279
44 Zheng, Y., Deng, J., Han, L., Zhuang, M.W., Xu, Y., Zhang, J. et al. (2022) SARS-CoV-2 NSP5 and N protein counteract the RIG-I signaling pathway by suppressing the formation of stress granules. Signal Transduct. Target. Ther. 7 , 22 10.1038/s41392-022-00878-3 35075101
45 Zhao, Y., Sui, L., Wu, P., Wang, W., Wang, Z., Yu, Y. et al. (2021) A dual-role of SARS-CoV-2 nucleocapsid protein in regulating innate immune response. Signal Transduct. Target. Ther. 6 , 331 10.1038/s41392-021-00742-w 34471099
46 Chen, K., Xiao, F., Hu, D., Ge, W., Tian, M., Wang, W. et al. (2020) SARS-CoV-2 nucleocapsid protein interacts with RIG-I and represses RIG-mediated IFN-β production. Viruses 13 , 47 10.3390/v13010047 33396605
47 Savellini, G.G., Anichini, G., Gandolfo, C. and Cusi, M.G. (2021) SARS-CoV-2 n protein targets TRIM25-mediated RIG-I activation to suppress innate immunity. Viruses 13 , 1439 10.3390/v13081439 34452305
48 Vazquez, C., Swanson, S.E., Negatu, S.G., Dittmar, M., Miller, J., Ramage, H.R. et al. (2021) SARS-CoV-2 viral proteins NSP1 and NSP13 inhibit interferon activation through distinct mechanisms. PLoS ONE 16 , e0253089 10.1371/journal.pone.0253089 34166398
49 Xia, H., Cao, Z., Xie, X., Zhang, X., Chen, J.Y.C., Wang, H. et al. (2020) Evasion of type I interferon by SARS-CoV-2. Cell Rep. 33 , 108234 10.1016/j.celrep.2020.108234 32979938
50 Zheng, Y., Zhuang, M.W., Han, L., Zhang, J., Nan, M.L., Zhan, P. et al. (2020) Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) membrane (M) protein inhibits type I and III interferon production by targeting RIG-I/MDA-5 signaling. Signal Transduct. Target. Ther. 5 , 299 10.1038/s41392-020-00438-7 33372174
51 Liu, G.Q., Lee, J.H., Parker, Z.M., Acharya, D., Chiang, J.J., van Gent, M. et al. (2021) ISG15-dependent activation of the sensor MDA5 is antagonized by the SARS-CoV-2 papain-like protease to evade host innate immunity. Nat. Microbiol. 6 , 467–478 10.1038/s41564-021-00884-1 33727702
52 Shi, H.-X., Yang, K., Liu, X., Liu, X.-Y., Wei, B., Shan, Y.-F. et al. (2010) Positive regulation of interferon regulatory factor 3 activation by Herc5 via ISG15 modification. Mol. Cell. Biol. 30 , 2424–2436 10.1128/MCB.01466-09 20308324
53 Shin, D., Mukherjee, R., Grewe, D., Bojkova, D., Baek, K., Bhattacharya, A. et al. (2020) Papain-like protease regulates SARS-CoV-2 viral spread and innate immunity. Nature 587 , 657–662 10.1038/s41586-020-2601-5 32726803
54 Wang, W., Zhou, Z., Xiao, X., Tian, Z., Dong, X., Wang, C. et al. (2021) SARS-CoV-2 nsp12 attenuates type I interferon production by inhibiting IRF3 nuclear translocation. Cell. Mol. Immunol. 18 , 945–953 10.1038/s41423-020-00619-y 33637958
55 Wu, J., Shi, Y., Pan, X., Wu, S., Hou, R., Zhang, Y. et al. (2021) SARS-CoV-2 ORF9b inhibits RIG-I-MAVS antiviral signaling by interrupting K63-linked ubiquitination of NEMO. Cell Rep. 34 , 108761 10.1016/j.celrep.2021.108761 33567255
56 Fung, S.Y., Siu, K.L., Lin, H., Chan, C.P., Yeung, M.L. and Jin, D.Y. (2022) SARS-CoV-2 NSP13 helicase suppresses interferon signaling by perturbing JAK1 phosphorylation of STAT1. Cell Biosci. 12 , 36 10.1186/s13578-022-00770-1 35317858
57 Feng, K., Min, Y.Q., Sun, X., Deng, F., Li, P., Wang, H. et al. (2021) Interactome profiling reveals interaction of SARS-CoV-2 NSP13 with host factor STAT1 to suppress interferon signaling. J. Mol. Cell Biol. 13 , 760–762 10.1093/jmcb/mjab068 34687317
58 Mu, J., Fang, Y., Yang, Q., Shu, T., Wang, A., Huang, M. et al. (2020) SARS-CoV-2 N protein antagonizes type I interferon signaling by suppressing phosphorylation and nuclear translocation of STAT1 and STAT2. Cell Discov. 6 , 65 10.1038/s41421-020-00208-3 32953130
59 Wang, R., Yang, X., Chang, M., Xue, Z., Wang, W., Bai, L. et al. (2021) ORF3a protein of severe acute respiratory syndrome coronavirus 2 inhibits interferon-activated Janus kinase/signal transducer and activator of transcription signaling via elevating suppressor of cytokine signaling 1. Front. Microbiol. 12 , 752597 10.3389/fmicb.2021.752597 34650546
60 Tang, S., Patel, A. and Krause, P.R. (2016) Herpes simplex virus ICP27 regulates alternative pre-mRNA polyadenylation and splicing in a sequence-dependent manner. Proc. Natl Acad. Sci. U.S.A. 113 , 12256–12561 10.1073/pnas.1609695113 27791013
61 Boudreault, S., Durand, M., Martineau, C.A., Perreault, J.P., Lemay, G. and Bisaillon, M. (2022) Reovirus μ2 protein modulates host cell alternative splicing by reducing protein levels of U5 snRNP core components. Nucleic Acids Res. 50 , 5263–5281 10.1093/nar/gkac272 35489070
62 Banerjee, A.K., Blanco, M.R., Bruce, E.A., Honson, D.D., Chen, L.M., Chow, A. et al. (2020) SARS-CoV-2 disrupts splicing, translation, and protein trafficking to suppress host defenses. Cell 183 , 1325–1339 10.1016/j.cell.2020.10.004 33080218
63 Kuss, S.K., Mata, M.A., Zhang, L. and Fontoura, B.M.A. (2013) Nuclear imprisonment: viral strategies to arrest host mRNA nuclear export. Viruses 5 , 1824–1849 10.3390/v5071824 23872491
64 Finkel, Y., Gluck, A., Nachshon, A., Winkler, R., Fisher, T., Rozman, B. et al. (2021) SARS-CoV-2 uses a multipronged strategy to impede host protein synthesis. Nature 594 , 240–245 10.1038/s41586-021-03610-3 33979833
65 Burke, J.M., St Clair, L.A., Perera, R. and Parker, R. (2021) SARS-CoV-2 infection triggers widespread host mRNA decay leading to an mRNA export block. RNA 27 , 1318–1329 10.1261/rna.078923.121 34315815
66 Zhang, K., Miorin, L., Makio, T., Dehghan, I., Gao, S., Xie, Y. et al. (2021) Nsp1 protein of SARS-CoV-2 disrupts the mRNA export machinery to inhibit host gene expression. Sci. Adv. 7 , eabe7386 10.1126/sciadv.abe7386 33547084
67 Hall, R., Guedan, A., Yap, M.W., Young, G.R., Harvey, R., Stoye, J.P. et al. (2022) SARS-CoV-2 ORF6 disrupts innate immune signalling by inhibiting cellular mRNA export. PLoS Pathog. 18 , e1010349 10.1371/journal.ppat.1010349 36007063
68 Addetia, A., Lieberman, N.A.P., Phung, Q., Hsiang, T.Y., Xie, H., Roychoudhury, P. et al. (2021) SARS-CoV-2 ORF6 disrupts bidirectional nucleocytoplasmic transport through interactions with Rae1 and Nup98. MBio 12 , e00065-21 10.1128/mBio.00065-21 33849972
69 Miorin, L., Kehrer, T., Sanchez-Aparicio, M.T., Zhang, K., Cohen, P., Patel, R.S. et al. (2020) SARS-CoV-2 Orf6 hijacks Nup98 to block STAT nuclear import and antagonize interferon signaling. Proc. Natl Acad. Sci. U.S.A. 117 , 28344–28354 10.1073/pnas.2016650117 33097660
70 Hoang, H.-D., Graber, T.E. and Alain, T. (2018) Battling for ribosomes: translational control at the forefront of the antiviral response. J. Mol. Biol. 430 , 1965–1992 10.1016/j.jmb.2018.04.040 29746850
71 Thoms, M., Buschauer, R., Ameismeier, M., Koepke, L., Denk, T., Hirschenberger, M. et al. (2020) Structural basis for translational shutdown and immune evasion by the Nsp1 protein of SARS-CoV-2. Science 369 , 1249–1256 10.1126/science.abc8665 32680882
72 Schubert, K., Karousis, E.D., Jomaa, A., Scaiola, A., Echeverria, B., Gurzeler, L.A. et al. (2020) SARS-CoV-2 Nsp1 binds the ribosomal mRNA channel to inhibit translation. Nat. Struct. Mol. Biol. 27 , 959–966 10.1038/s41594-020-0511-8 32908316
73 Slobodin, B., Sehrawat, U., Lev, A., Hayat, D., Zuckerman, B., Fraticelli, D. et al. (2022) Cap-independent translation and a precisely located RNA sequence enable SARS-CoV-2 to control host translation and escape anti-viral response. Nucleic Acids Res. 50 , 8080–8092 10.1093/nar/gkac615 35849342
74 Hsu, J.C.C., Laurent-Rolle, M., Pawlak, J.B., Wilen, C.B. and Cresswell, P. (2021) Translational shutdown and evasion of the innate immune response by SARS-CoV-2 NSP14 protein. Proc. Natl Acad. Sci. U.S.A. 118 , e2101161118 10.1073/pnas.2101161118 34045361
75 Xu, Z., Choi, J.H., Dai, D.L., Luo, J., Ladak, R.J., Li, Q. et al. (2022) SARS-CoV-2 impairs interferon production via NSP2-induced repression of mRNA translation. Proc. Natl Acad. Sci. U.S.A. 119 , e2204539119 10.1073/pnas.2204539119 35878012
76 Mayya, V.K., Flamand, M.N., Lambert, A.M., Jafarnejad, S.M., Wohlschlegel, J.A., Sonenberg, N. et al. (2021) microRNA-mediated translation repression through GYF-1 and IFE-4 in C. elegans development. Nucleic Acids Res. 49 , 4803–4815 10.1093/nar/gkab162 33758928
77 Naeli, P., Zhang, X., Snell, P.H., Chatterjee, S., Kamran, M. and Ladak, R.J.) SARS-CoV-2 protein NSP2 enhances microRNA-mediated translational repression. bioRxiv 10.1101/2023.01.01.522328
78 Mishra, R., Kumar, A., Ingle, H. and Kumar, H. (2019) The interplay between viral-derived miRNAs and host immunity during infection. Front. Immunol. 10 , 3079 10.3389/fimmu.2019.03079 32038626
79 Pawlica, P., Yario, T.A., White, S., Wang, J., Moss, W.N., Hui, P. et al. (2021) SARS-CoV-2 expresses a microRNA-like small RNA able to selectively repress host genes. Proc. Natl Acad. Sci. U.S.A. 118 , e2116668118 10.1073/pnas.2116668118 34903581
80 Singh, M., Chazal, M., Quarato, P., Bourdon, L., Malabat, C., Vallet, T. et al. (2022) A virus-derived microRNA targets immune response genes during SARS-CoV-2 infection. EMBO Rep. 23 , e54341 10.15252/embr.202154341 34914162
81 Zhu, Y., Zhang, Z., Song, J., Qian, W., Gu, X., Yang, C. et al. (2021) SARS-CoV-2-encoded MiRNAs inhibit host type I interferon pathway and mediate allelic differential expression of susceptible gene. Front. Immunol. 12 , 767726 10.3389/fimmu.2021.767726 35003084
82 Morales, L., Oliveros, J.C., Fernandez-Delgado, R., tenOever, B.R., Enjuanes, L. and Sola, I. (2017) SARS-CoV-encoded small RNAs contribute to infection-associated lung pathology. Cell Host Microbe 21 , 344–355 10.1016/j.chom.2017.01.015 28216251
83 Zhang, X., Chapat, C., Wang, P., Choi, J.H., Li, Q., Luo, J. et al. (2021) MicroRNA-induced translational control of antiviral immunity by the cap-binding protein 4EHP. Mol. Cell 81 , 1187–1199 10.1016/j.molcel.2021.01.030 33581076
84 Witwer, K.W., Sisk, J.M., Gama, L. and Clements, J.E. (2010) MicroRNA regulation of IFN-beta protein expression: rapid and sensitive modulation of the innate immune response. J. Immunol. 184 , 2369–2376 10.4049/jimmunol.0902712 20130213
85 Li, Y., Fan, X., He, X., Sun, H., Zou, Z., Yuan, H. et al. (2012) MicroRNA-466l inhibits antiviral innate immune response by targeting interferon-alpha. Cell. Mol. Immunol. 9 , 497–502 10.1038/cmi.2012.35 23042536